Member Exclusive

Epigenetic biomarker discovery applied to diagnosis, monitoring and prognosis of diseases associated with aberrant gene expression

In this interview, EpigenomicsNet is in discussion with Dr Alexandre Akoulitchev, Chief Scientific Officer at Oxford BioDynamics (UK). Dr Akoulitchev joins us to tell us about the work going on at Oxford BioDynamics, with a focus on the biomarker discovery platform EpiSwitch™, including a brief overview of how it works and its main advantages, before concluding with a brief look at the current and upcoming projects at Oxford BioDynamics.

Go to the profile of Georgia Patey
Apr 07, 2016

Please sign in or register for FREE

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.